Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Payables (2016 - 2025)

Seres Therapeutics' Payables history spans 11 years, with the latest figure at $1.7 million for Q3 2025.

  • For Q3 2025, Payables fell 79.68% year-over-year to $1.7 million; the TTM value through Sep 2025 reached $1.7 million, down 79.68%, while the annual FY2024 figure was $4.1 million, 12.03% up from the prior year.
  • Payables for Q3 2025 was $1.7 million at Seres Therapeutics, down from $2.2 million in the prior quarter.
  • Across five years, Payables topped out at $18.0 million in Q3 2021 and bottomed at $1.7 million in Q3 2025.
  • The 5-year median for Payables is $8.3 million (2024), against an average of $8.8 million.
  • The largest annual shift saw Payables soared 207.13% in 2021 before it crashed 79.68% in 2025.
  • A 5-year view of Payables shows it stood at $13.7 million in 2021, then surged by 30.29% to $17.9 million in 2022, then plummeted by 79.65% to $3.6 million in 2023, then grew by 12.03% to $4.1 million in 2024, then crashed by 58.89% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Payables are $1.7 million (Q3 2025), $2.2 million (Q2 2025), and $2.2 million (Q1 2025).